instruction
stringlengths 33
156
| input
float64 | output
stringlengths 120
1.97k
|
---|---|---|
Does Abatacept and Fruquintinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Fruquintinib can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Fusidic acid interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Fusidic acid can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Galantamine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Galantamine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Gefitinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Gefitinib can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Gemcitabine interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Gemtuzumab ozogamicin interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Gilteritinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Gilteritinib can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Glasdegib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates. In short, The metabolism of Glasdegib can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Glatiramer interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Glatiramer, and the severity of the interaction is major. |
Does Abatacept and Gliclazide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Gliclazide can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Glimepiride interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Glimepiride can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Glipizide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Glipizide can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Gliquidone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Gliquidone can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Glyburide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Glyburide can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Golimumab interact? | null | Concomitant use of abatacept and TNF-α inhibitors, which are both immunosuppressive agents, increases the risk of serious infection with no therapeutic benefit. In short, The risk or severity of infection can be increased when Golimumab is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Guselkumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Guselkumab, and the severity of the interaction is major. |
Does Abatacept and Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Haloperidol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Haloperidol can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Halothane interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates. In short, The metabolism of Halothane can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Hepatitis A Vaccine interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Hepatitis B Vaccine (Recombinant) interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Hydrocodone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Hydrocodone can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Hydrocortisone acetate interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Hydrocortisone acetate can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Hydrocortisone butyrate interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Hydrocortisone butyrate can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Hydrocortisone phosphate interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Hydrocortisone phosphate can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Hydrocortisone succinate interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Hydrocortisone succinate, and the severity of the interaction is major. |
Does Abatacept and Hydrocortisone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Hydrocortisone can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Hydromorphone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Hydromorphone can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Hydroxychloroquine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Hydroxychloroquine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Hydroxyprogesterone caproate interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Hydroxyprogesterone caproate can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Hydroxyurea interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Hydroxyzine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Hydroxyzine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Ibritumomab tiuxetan interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Ibrutinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Ibrutinib can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Ibuprofen interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Ibuprofen can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Idarubicin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Idarubicin can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Idelalisib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Idelalisib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Ifosfamide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates with a narrow therapeutic index. In short, The metabolism of Ifosfamide can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Iloperidone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Iloperidone can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Imatinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Imatinib can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Imipramine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Imipramine can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Indinavir interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Indinavir can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Indomethacin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Indomethacin can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Inebilizumab interact? | null | Inebilizumab has immunosuppressive properties. The combination of inebilizumab with other immunosuppressants may increase the risk of infection. In short, The risk or severity of infection can be increased when Abatacept is combined with Inebilizumab, and the severity of the interaction is minor. |
Does Abatacept and Infigratinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Infigratinib can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Infliximab interact? | null | Concomitant use of abatacept and TNF-α inhibitors, which are both immunosuppressive agents, increases the risk of serious infection with no therapeutic benefit. In short, The risk or severity of infection can be increased when Infliximab is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Interferon alfa-2a interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Interferon alfa-2b interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Interferon alfa-n3 interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Interferon beta-1b interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Interferon gamma-1b interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Iptacopan interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Iptacopan can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Irbesartan interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Irbesartan can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Irinotecan interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Irinotecan can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Isavuconazole interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Isavuconazole can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Isavuconazonium interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Isavuconazonium can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Isoflurane interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Isoflurane can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Istradefylline interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Istradefylline can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Ivacaftor interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Ivacaftor can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Ivosidenib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Ivosidenib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Ixabepilone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Ixabepilone can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Ixazomib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Ixazomib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Ixekizumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Ixekizumab, and the severity of the interaction is major. |
Does Abatacept and Janssen COVID-19 Vaccine interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Ketamine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Ketamine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Ketorolac interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Ketorolac can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Labetalol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Labetalol can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Lacosamide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Lacosamide can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Lansoprazole interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Lansoprazole can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Lapatinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Lapatinib can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Lefamulin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Lefamulin can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Leflunomide interact? | null | The immunosuppressive effects of leflunomide may be augmented by the concurrent administration of immunosuppressive agents, leading to an increased risk of serious infection and/or lymphoproliferative disorders resulting from bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Leflunomide, and the severity of the interaction is moderate. |
Does Abatacept and Lemborexant interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Lemborexant can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Lenalidomide interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Lercanidipine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Lercanidipine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Letrozole interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates. In short, The metabolism of Letrozole can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Levamlodipine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Levamlodipine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Levobupivacaine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Levobupivacaine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Levonorgestrel interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Levonorgestrel can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Lidocaine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Lidocaine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Linagliptin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Linagliptin can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Linezolid interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Linezolid is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Magnesium interact? | null | Co-administration of magnesium with certain immunosuppressive agents (cyclosporin, ritodrine) may lead to a decrease in serum concentrations of magnesium. In short, The serum concentration of Magnesium can be decreased when it is combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Maprotiline interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Maprotiline can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Mavacamten interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Mavacamten can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Measles virus vaccine live attenuated interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Mechlorethamine interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Meclizine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Meclizine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Mefenamic acid interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Mefenamic acid can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Melatonin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Melatonin can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Meloxicam interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Meloxicam can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Melphalan interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Melphalan is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Meperidine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Meperidine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Mepolizumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Mepolizumab, and the severity of the interaction is major. |
Does Abatacept and Mercaptopurine interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Metamfetamine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Metamfetamine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Methadone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Methadone can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Methimazole interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Methimazole is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Methotrexate interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Methotrexate can be increased when combined with Abatacept, and the severity of the interaction is major. |